What are the latest advances in the treatment of Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Newest Advances in Parkinson's Treatment

For advanced Parkinson's disease with motor fluctuations, subthalamic nucleus deep brain stimulation (STN-DBS) remains the most effective intervention with the strongest long-term evidence, showing sustained benefit beyond 15 years, while newer continuous dopaminergic delivery systems (levodopa-carbidopa intestinal gel and subcutaneous apomorphine) offer moderate improvements for patients who cannot undergo surgery. 1

Invasive Therapies for Advanced Disease (Strongest Evidence)

The 2024 European Academy of Neurology/Movement Disorder Society guideline establishes a clear hierarchy for advanced PD with medically unresponsive fluctuations 1:

Deep Brain Stimulation (First-Line for Surgical Candidates)

  • STN-DBS has the most extensive evidence from 5 randomized controlled trials showing large improvements in motor impairment, fluctuations, and dyskinesia 1
  • Effectiveness persists beyond 15 years based on multiple meta-analyses 1
  • GPi-DBS is equally effective to STN-DBS for motor symptoms over 3 years, though it reduces levodopa dosage less effectively 1
  • The choice between STN and GPi targets should be left to the treatment center based on individual patient factors 1

Continuous Dopaminergic Delivery (For Non-Surgical Candidates)

Levodopa-Carbidopa Intestinal Gel (LCIG):

  • Two RCTs (including DYSCOVER trial) demonstrate moderate increases in on-time without troublesome dyskinesia 1
  • Moderate decrease in daily off-time compared to oral treatment over 3 months 1
  • Registry data shows sustained reduction in off-time and dyskinesia for 2-3 years 1
  • Caveat: Longer controlled data beyond 12 months still needed 1

Continuous Apomorphine Infusion (CAI):

  • One RCT showed moderate improvement in daily on-time without troublesome dyskinesia over 12 weeks 1
  • Moderate improvement in daily off-time versus best medical treatment 1
  • Important limitation: Quality of life and motor disability did not significantly improve 1
  • Retrospective data confirms sustained reduction in motor fluctuations for at least 2 years 1

Novel Symptomatic Treatments (Emerging Evidence)

New Levodopa Formulations

Recent developments include extended-release oral levodopa (IPX203), inhaled levodopa powder, and subcutaneous levodopa infusions (foslevodopa/foscarbidopa, ND0612) aimed at providing more continuous dopaminergic stimulation 2

Novel Dopamine Agonists

Tavapadon, a selective D1/D5 receptor partial agonist, has shown efficacy as monotherapy in early PD and as adjunct therapy in patients with motor fluctuations 2

Amantadine

Increasing evidence supports amantadine's symptomatic efficacy for treating levodopa-induced dyskinesia and motor fluctuations 2

Disease-Modifying Therapies (Investigational)

While no therapy has conclusive disease-modifying evidence yet, the most promising approaches in late-stage development include 2, 3, 4:

α-Synuclein Targeted Therapies

  • Active immunization: PD01A and UB-312 show favorable safety profiles and peripheral target engagement 5
  • Passive immunotherapy: Prasinezumab and cinpanemab demonstrated good safety but failed primary endpoints in Phase II trials (PASADENA, SPARK) 5
  • Critical gap: Biological target engagement has not translated to meaningful clinical benefit 5

Metabolic and Neuroprotective Agents

  • GLP-1 receptor agonists show promise for neuroprotection 2, 3
  • LRRK2 inhibitors targeting leucine-rich repeat kinase 2 pathway 2
  • GBA pathway modulators including glucocerebrosidase-targeted interventions and glucosylceramide synthase inhibitors 6, 2

Emerging Technologies

  • Adaptive deep brain stimulation for more responsive neuromodulation 6
  • Transcranial temporal interference stimulation as non-invasive alternative 6
  • Stem cell and gene therapies remain experimental 6, 4

Clinical Decision Algorithm

For patients with severe motor fluctuations:

  1. Assess surgical candidacy (age, comorbidities, cognitive status, psychiatric symptoms) 1
  2. If surgical candidate → STN-DBS or GPi-DBS (strongest evidence) 1
  3. If not surgical candidate → Consider LCIG or CAI based on contraindications 1

Key contraindications to consider 1:

  • DBS: Neurosurgical contraindications, severe neuropsychiatric disorders, advanced age with multimorbidity
  • LCIG: Conditions interfering with PEG tube placement or GI absorption, severe cognitive/psychiatric symptoms
  • CAI: ECG alterations, hemolytic anemia, severe psychiatric/cognitive symptoms, orthostatic hypotension
  • All invasive therapies: Lack of levodopa sensitivity

Important Caveats

Adverse events are the main limitation of invasive therapies, including surgery/device complications, neuropsychiatric symptoms, GI complications (LCIG), dysarthria/gait impairment (DBS), and dyskinesia (CAI) 1

The majority of novel disease-modifying therapies remain investigational and require validation through additional randomized controlled trials 6. Current pharmacotherapy remains largely symptomatic and does not halt disease progression 2, 3.

References

5
Research

Progress of Immunotherapies in Parkinson's Disease.

CNS neuroscience & therapeutics, 2026

6
Research

Novel treatments for Parkinson's disease.

Chinese medical journal, 2026

Related Questions

In a 70-year-old bedridden female with Parkinson disease on levodopa/carbidopa, who has no fever or cough, a normal chest X‑ray, urinalysis showing pyuria with neutrophil predominance, elevated ferritin, modestly elevated procalcitonin, and markedly elevated D‑dimer, what is the clinical impression and recommended management?
Can an adult patient with Parkinson's disease safely take carbidopa (levodopa‑carbidopa) together with promethazine?
What is the current treatment algorithm for Parkinson's disease, including first‑line therapy and options based on patient age and symptom severity?
Does Sinemet (carbidopa/levodopa) increase dopamine levels in the brain?
What is the recommended management for Parkinson's disease, including pharmacologic and non‑pharmacologic treatments?
Should vaginal progesterone be administered after a confirmed missed miscarriage?
What does radiotracer activity in the salivary glands and physiologic myocardial uptake on a technetium‑99m sestamibi parathyroid scan indicate when the parathyroid area shows only faint sestamibi uptake?
As a primary care physician, how should I transition a patient currently taking Armour Thyroid (desiccated thyroid extract) 15 mg (5 tablets) each morning to levothyroxine, and what initial levothyroxine dose should I prescribe given a serum TSH of 1.07 µIU/mL with low free T4 and low free T3?
What are the first-line oral antibiotic options for non-purulent cellulitis?
How should I manage an 80-year-old male with lower extremity swelling and rest pain who has moderate arterial occlusive disease on arterial duplex?
What are the symptoms of insulinoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.